AB Science announced new data reporting long-term survival analysis of masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis (ALS) have been…
Alexion Pharmaceuticals announced positive topline results from a Phase 3 study evaluating the safety and efficacy of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).…
A new study called “MRI Biomarkers of Disease Progression in Inherited Neuropathies” received funding thanks to a grant from the National Center for Advancing Translational…
An assistant professor of radiology and of neurology at the Washington University St. Louis, School of Medicine received a $2.3 million grant from the National…
Clinical trials are complex, multifaceted endeavors requiring enormous attention to detail, follow up, and passion for the patient. That’s why TrialSite considers the Clinical Research Coordinator…
Biogen and collaboration partner Eisai announced the U.S. FDA has granted accelerated approval for Aduhelm (aducanumab-avwa) for the treatment of Alzheimer’s disease. The accelerated approval was…
Hoag’s Pickup Family Neurosciences Institute has started recruiting volunteers for a study testing an investigational treatment that aims to help prevent the earliest stages of…
Annovis Bio reported positive results from a phase 2a trial evaluating ANVS401 versus placebo in patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD). Efficacy…
AB Sciences announced that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide. This decision follows…
Neuroscientists at Northwell Health’s Institute for Neurology and Neurosurgery and The Feinstein Institutes for Medical Research (FIMR) will conduct a multi-centered, randomized, Phase 3 research…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
